Treatment of acquired severe aplastic anemia

Emmanuel Katsanis, Norma K.C. Ramsay

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


The management of patients with acquired severe aplastic anemia has been directed at intensive supportive care and restoration of normal marrow function. Bone marrow transplantation remains the treatment of choice with -70% long-term survivors, after related histocompatible transplants. More intensive conditioning regimens, using cyclophosphamide with some form of radiation, have decreased the incidence of graft rejection to <5%. Immu-nosuppression with antilymphocyte (ALG) or antithymocyte (ATG) globulin may induce complete or partial hematologic recovery in 35-70% of patients, with 1- and 2-year survival rates in the range of 50-70% and 45-55%, respectively. The role of high-dose corticosteroids, cyclosporine A, and colony-stimulating factors in the management of patients with acquired severe aplastic anemia is less clear and requires further investigation. Finally, androgens, either alone or in combination with other agents, do not seem to have a place in the treatment of severe bone marrow aplasia.

Original languageEnglish (US)
Pages (from-to)360-367
Number of pages8
JournalAmerican Journal of Pediatric Hematology/Oncology
Issue number3
StatePublished - 1989


  • Acquired severe aplastic anemia
  • Antilymphocyte globulin
  • Antithymocyte globulin
  • Bone marrow transplantation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Treatment of acquired severe aplastic anemia'. Together they form a unique fingerprint.

Cite this